News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AVANIR Pharmaceuticals Reports Fiscal 2012 Fourth Quarter and Year-End Financial and Business Results
December 13, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ALISO VIEJO, Calif., Dec. 12, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve months ended September 30, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoff Tracker
Vistagen cuts workforce for second time in 2026
November 2, 2026
·
114 min read
·
BioSpace Editorial Staff
Cell therapy
Cell therapy investment grows as safety events rankle Big Pharma’s CAR T autoimmune push
November 2, 2026
·
3 min read
·
Annalee Armstrong
Drug Development
Can Saudi Arabia’s burgeoning biotech hub withstand geopolitical pressures?
November 2, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Earnings
AstraZeneca employs $1.5B cost savings to reinvest back into growth
October 30, 2026
·
3 min read
·
Annalee Armstrong
